Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Wansbrough-Jones

Showing results (31-40 of 31) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 31 results.
Lancet (London, England)|March 16, 2020
Rifampicin and clarithromycin (extended release) versus rifampicin and streptomycin for limited Buruli ulcer lesions: a randomised, open-label, non-inferiority phase 3 trialRichard O Phillips, Jérôme Robert, Kabiru Mohamed Abass, et al.
Pageof 4

Showing results (31-40 of 31) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 31 results.
Lancet (London, England)|March 16, 2020
Rifampicin and clarithromycin (extended release) versus rifampicin and streptomycin for limited Buruli ulcer lesions: a randomised, open-label, non-inferiority phase 3 trialRichard O Phillips, Jérôme Robert, Kabiru Mohamed Abass, et al.
Pageof 4